Taeyoung to Sack Executives, Cut Employees' Salaries to Save Company 
Meta AI to Supercharge WhatsApp, Facebook, Instagram via Powerful Integration 
Adidas Ignites Passion with 2024 Athlete Pack Including 49 Footwear Models 
Google Fired Workers Protesting Over Cloud Contract Deal With Israel 
Kawhi Leonard and New Balance Launch the Highly Anticipated KAWHI IV Sneaker 
Huawei Unveils Pura 70 Series to Rival Apple's Dominance in China's Smartphone Arena 
Hyundai Halts Advertising on X Amid Antisemitism Row 
Adidas Unveils Innovative Team Kits for Paris 2024 Olympics and Paralympics 
LG Electronics Eyes $1 Billion Through Bond Deal 
Canada Set to Enforce OECD Crypto Tax Standards by 2026 
Samsung's Exynos 2500 Rumored to Eclipse Snapdragon 8 Gen 4 in Power Efficiency With 3nm SoC 
Low pay and few contracts make freelance journalism a bleak prospect in 2024 
Mister Donut and Gion Tsujiri Unite Once More for Kyoto-Inspired Donut Delights 
Polestar to Launch Polestar 4 Pure EV in South Korea 
Apple Pulls WhatsApp, Threads from China Store; US Moves to Force TikTok Sale 
Samsung Implements Emergency 6-Day Work Week to Combat Slowing Growth 
Nissan Cuts Profit Forecasts Amidst Sales Slump and Natural Disaster 
CAMBRIDGE, Mass., Sept. 26, 2016 -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of migraine in adults, with or without aura, announced today it will provide a corporate overview at the Ladenburg Thalmann 2016 Healthcare Conference, being held in New York City on September 27, 2016.
| Ladenburg Thalmann 2016 Healthcare Conference | |
| Date: | Tuesday, September 27 |
| Time: | 11:30am Eastern Time |
| Location: | Sofitel Hotel New York, Odeon Room |
| Webcast: | http://wsw.com/webcast/ladenburg2/clcd |
About CoLucid Pharmaceuticals, Inc.
CoLucid was founded in 2005 and is developing lasmiditan oral tablets for the acute treatment of migraine headaches in adults and intravenous lasmiditan for the acute treatment of headache pain associated with migraine in adults in emergency room and other urgent care settings.
CONTACT Thomas Mathers Chief Executive Officer CoLucid Pharmaceuticals, Inc. (857) 285-6494 Hans Vitzthum Managing Director LifeSci Advisors, LLC. (212) 915-2568
